Two Independent Studies Use the GeoMx Digital Spatial Profiler to Investigate the Role of the Tumor and Micro-environment in Immunotherapy Response
The GeoMx Digital Spatial Profiler was used to characterize pretreatment tumor biopsies and revealed differential expression of several potential biomarkers, including B2M and CD3. The first publication was led by researchers at the DSP Center of Excellence at the
“We used the DSP platform to characterize pretreatment tumor biopsies to understand how the preexisting immune status of the melanoma biopsies predicts response,” said
The second study, entitled “Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma,” was led by Dr.
“In this study, we were interested in characterizing predictors of response to neoadjuvant nivolumab or nivolumab and ipilimumab. DSP technology enabled us to quantify protein expression specifically in tumor infiltrating immune cells in both pre-treatment and on-treatment biopsy specimens—many of which were small needle core biopsy specimens with a limited number of tumor and/or immune cells,” said Dr.
“Each of these studies independently demonstrates the value of the Digital Spatial Profiling approach in identifying potential biomarkers that may guide patient management in terms of therapeutic strategy and follow up,” said
The data for both publications was generated as part of the DSP Technology Access Program, under which samples are processed at
The GeoMx Digital Spatial Profiler enables researchers to rapidly and quantitatively characterize tissue morphology with a high-throughput, high-plex RNA and protein profiling system that preserves precious samples for future analyses.
Interested parties can learn more about DSP by visiting https://www.nanostring.com/scientific-content/technology-overview/digital-spatial-profiling-technology.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the performance and attributes of Digital Spatial Profiling, including the commercial availability of DSP and the potential ability of DSP to identify biomarkers that can predict therapeutic response to immunotherapy. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; the impact of competition; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in our filings with the
Vice President, Investor Relations & Corporate Communications
Source: NanoString Technologies, Inc.